Annual Cash & Cash Equivalents
$4.46 M
+$604.00 K+15.67%
31 December 2023
Summary:
ReShape Lifesciences annual cash & cash equivalents is currently $4.46 million, with the most recent change of +$604.00 thousand (+15.67%) on 31 December 2023. During the last 3 years, it has risen by +$1.50 million (+50.79%). RSLS annual cash & cash equivalents is now -90.85% below its all-time high of $48.73 million, reached on 31 December 2007.RSLS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$743.00 K
-$310.00 K-29.44%
30 September 2024
Summary:
ReShape Lifesciences quarterly cash and cash equivalents is currently $743.00 thousand, with the most recent change of -$310.00 thousand (-29.44%) on 30 September 2024. Over the past year, it has dropped by -$706.00 thousand (-48.72%). RSLS quarterly cash and cash equivalents is now -98.48% below its all-time high of $48.73 million, reached on 31 December 2007.RSLS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RSLS Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +15.7% | -48.7% |
| 3 y3 years | +50.8% | -97.5% |
| 5 y5 years | -19.6% | -90.4% |
RSLS Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -80.4% | +50.8% | -97.5% | at low |
| 5 y | 5 years | -80.4% | +51.9% | -98.2% | at low |
| alltime | all time | -90.8% | +51.9% | -98.5% | +57.1% |
ReShape Lifesciences Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $743.00 K(-29.4%) |
| June 2024 | - | $1.05 M(-55.7%) |
| Mar 2024 | - | $2.38 M(-46.6%) |
| Dec 2023 | $4.46 M(+15.7%) | $4.46 M(+207.7%) |
| Sept 2023 | - | $1.45 M(-68.3%) |
| June 2023 | - | $4.57 M(-49.2%) |
| Mar 2023 | - | $8.98 M(+133.0%) |
| Dec 2022 | $3.85 M(-83.1%) | $3.85 M(-37.3%) |
| Sept 2022 | - | $6.15 M(-46.5%) |
| June 2022 | - | $11.49 M(-25.4%) |
| Mar 2022 | - | $15.41 M(-32.3%) |
| Dec 2021 | $22.77 M(+669.9%) | $22.77 M(-22.2%) |
| Sept 2021 | - | $29.24 M(-27.2%) |
| June 2021 | - | $40.16 M(+4382.5%) |
| Mar 2021 | - | $896.00 K(-69.7%) |
| Dec 2020 | $2.96 M(+0.7%) | $2.96 M(+59.2%) |
| Sept 2020 | - | $1.86 M(+21.7%) |
| June 2020 | - | $1.53 M(-27.9%) |
| Mar 2020 | - | $2.12 M(-27.9%) |
| Dec 2019 | $2.94 M(-47.1%) | $2.94 M(-62.0%) |
| Sept 2019 | - | $7.72 M(+77.2%) |
| June 2019 | - | $4.36 M(+138.2%) |
| Mar 2019 | - | $1.83 M(-67.1%) |
| Dec 2018 | $5.55 M(-45.4%) | $5.55 M(+1073.2%) |
| Sept 2018 | - | $472.90 K(-74.6%) |
| June 2018 | - | $1.86 M(+121.4%) |
| Mar 2018 | - | $841.60 K(-91.7%) |
| Dec 2017 | $10.16 M(+207.0%) | $10.16 M(-56.6%) |
| Sept 2017 | - | $23.43 M(+109.3%) |
| June 2017 | - | $11.20 M(-40.1%) |
| Mar 2017 | - | $18.68 M(+464.2%) |
| Dec 2016 | $3.31 M(-58.2%) | $3.31 M(-51.6%) |
| Sept 2016 | - | $6.84 M(-40.6%) |
| June 2016 | - | $11.52 M(+3.3%) |
| Mar 2016 | - | $11.15 M(+40.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $7.93 M(-31.8%) | $7.93 M(-35.3%) |
| Sept 2015 | - | $12.26 M(+155.5%) |
| June 2015 | - | $4.80 M(-58.0%) |
| Mar 2015 | - | $11.43 M(-1.6%) |
| Dec 2014 | $11.62 M(-50.1%) | $11.62 M(-28.6%) |
| Sept 2014 | - | $16.27 M(-24.9%) |
| June 2014 | - | $21.67 M(-11.3%) |
| Mar 2014 | - | $24.44 M(+4.9%) |
| Dec 2013 | $23.30 M(+4.4%) | $23.30 M(+10.2%) |
| Sept 2013 | - | $21.14 M(-8.4%) |
| June 2013 | - | $23.09 M(-21.5%) |
| Mar 2013 | - | $29.40 M(+31.8%) |
| Dec 2012 | $22.31 M(-21.7%) | $22.31 M(-18.0%) |
| Sept 2012 | - | $27.21 M(+2.5%) |
| June 2012 | - | $26.55 M(+29.4%) |
| Mar 2012 | - | $20.52 M(-28.0%) |
| Dec 2011 | $28.49 M(-7.6%) | $28.49 M(-12.2%) |
| Sept 2011 | - | $32.44 M(+19.2%) |
| June 2011 | - | $27.21 M(-9.2%) |
| Mar 2011 | - | $29.96 M(-2.9%) |
| Dec 2010 | $30.84 M(+111.0%) | $30.84 M(+145.7%) |
| Sept 2010 | - | $12.55 M(+24.6%) |
| June 2010 | - | $10.08 M(-30.8%) |
| Mar 2010 | - | $14.55 M(-0.4%) |
| Dec 2009 | $14.62 M(-30.6%) | $14.62 M(-46.0%) |
| Sept 2009 | - | $27.05 M(-21.7%) |
| June 2009 | - | $34.57 M(+0.7%) |
| Mar 2009 | - | $34.32 M(+63.0%) |
| Dec 2008 | $21.06 M(-56.8%) | $21.06 M(+7.4%) |
| Sept 2008 | - | $19.60 M(-44.1%) |
| June 2008 | - | $35.06 M(-15.5%) |
| Mar 2008 | - | $41.47 M(-14.9%) |
| Dec 2007 | $48.73 M(+177.9%) | $48.73 M(+206.8%) |
| Sept 2007 | - | $15.88 M(-9.4%) |
| Dec 2006 | $17.54 M(+63.6%) | $17.54 M(+63.6%) |
| Dec 2005 | $10.72 M | $10.72 M |
FAQ
- What is ReShape Lifesciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ReShape Lifesciences?
- What is ReShape Lifesciences annual cash & cash equivalents year-on-year change?
- What is ReShape Lifesciences quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for ReShape Lifesciences?
- What is ReShape Lifesciences quarterly cash and cash equivalents year-on-year change?
What is ReShape Lifesciences annual cash & cash equivalents?
The current annual cash & cash equivalents of RSLS is $4.46 M
What is the all time high annual cash & cash equivalents for ReShape Lifesciences?
ReShape Lifesciences all-time high annual cash & cash equivalents is $48.73 M
What is ReShape Lifesciences annual cash & cash equivalents year-on-year change?
Over the past year, RSLS annual cash & cash equivalents has changed by +$604.00 K (+15.67%)
What is ReShape Lifesciences quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RSLS is $743.00 K
What is the all time high quarterly cash and cash equivalents for ReShape Lifesciences?
ReShape Lifesciences all-time high quarterly cash and cash equivalents is $48.73 M
What is ReShape Lifesciences quarterly cash and cash equivalents year-on-year change?
Over the past year, RSLS quarterly cash and cash equivalents has changed by -$706.00 K (-48.72%)